Financial Performance - The Company's net sales for the 13 weeks ended November 30, 2025, were $17.3 million, representing a 20.3% increase from $14.4 million in the prior year, while net sales for the 39 weeks were $49.1 million, an 8.9% increase from $45.1 million [72][84]. - Gross profit for the 13 weeks ended November 30, 2025, was $5.9 million, a 54.2% increase from $3.8 million in the prior year, and for the 39 weeks, it was $15.7 million, up 24.1% from $12.7 million [83][91]. - Earnings before income taxes increased by 86.7% to $4.0 million for the 13 weeks and by 58.1% to $10.0 million for the 39 weeks ended November 30, 2025 [75][76]. - Net earnings for the 13 weeks ended November 30, 2025, were $3.0 million, an 87.1% increase from $1.6 million in the prior year, and for the 39 weeks, net earnings were $7.4 million, up 60.4% from $4.6 million [96]. Profitability Metrics - Gross profit margins were 34.1% for the 13 weeks and 32.0% for the 39 weeks ended November 30, 2025, compared to 26.6% and 28.1% in the prior year, respectively [74][87]. - Basic and diluted earnings per share for the 39 weeks ended November 30, 2025, were $0.37, an increase of 60.87% compared to $0.23 for the same period in 2024 [97]. Expenses and Income - Selling, general and administrative expenses increased by 14.0% to $2.3 million for the 13 weeks and by 11.2% to $6.8 million for the 39 weeks ended November 30, 2025 [88][89]. - Interest income increased by 18.3% to $343,000 for the 13 weeks and by 24.5% to $1.1 million for the 39 weeks ended November 30, 2025, primarily due to tax refunds and foreign exchange gains [92]. - The effective tax rates for the 13 weeks and 39 weeks ended November 30, 2025, were 26.0% and 25.6%, respectively, compared to 26.2% and 26.7% in the prior year [95]. Cash Flow and Liquidity - Net cash provided by operating activities for the 39 weeks ended November 30, 2025, was $3.748 million, a decrease of 18.2% from $4.581 million in the prior year [99]. - Cash and cash equivalents and marketable securities totaled $63.558 million as of November 30, 2025, down by $5.276 million from $68.834 million on March 2, 2025 [98]. - The current ratio improved to 15.8 to 1.0 at November 30, 2025, compared to 9.7 to 1.0 at March 2, 2025 [103]. Shareholder Returns - The company repurchased shares worth $2.2 million during the 39 weeks ended November 30, 2025, down from $4.3 million in the same period in 2024 [102]. - The company paid $7.5 million in cash dividends during the 39-week period ended November 30, 2025, compared to $7.6 million in the prior year [102]. Future Outlook - The company expects to file a registration statement to offer up to $50 million in shares of common stock under an Equity Distribution Agreement [106]. - The company believes its financial resources will be sufficient for continued investment in working capital and general corporate purposes for the foreseeable future [105]. - The company is not engaged in any off-balance sheet financing arrangements, ensuring liquidity is not dependent on such methods [109]. Other Considerations - The Company recorded a storm damage charge of $1.1 million in the prior year, with no corresponding charges in the current year, positively impacting earnings [77]. - The company continues to face inflation in raw material costs but has largely mitigated its impact through pricing adjustments [78]. - Accounts payable increased by 30% at November 30, 2025, compared to March 2, 2025, primarily due to timing of vendor payments [101].

https://files.reportify.cc/media/production/PKE20f7886d4cf65be4b8395bc2b35e14cf.jpg NEWS RELEASE Contact: Donna D'Amico-Annitto 486 North Oliver Road, Bldg. Z Newton, Kansas 67114 (316) 283-6500 PARK AEROSPACE CORP. REPORTS THIRD QUARTER RESULTS Newton, Kansas, Tuesday, January 13, 2026…..Park Aerospace Corp. (NYSE-PKE) reported results for the 2026 fiscal year third quarter ended November 30, 2025. The Company will conduct a conference call to discuss its financial results and other matters at 5:00 p.m. ES ...

Exhibit 99.2 FAST TRACK GROUP INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS F-2 FAST TRACK GROUP UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Stated in US Dollars, except for number of shares) | | For the Six Months Ended August 31, | | | --- | --- | --- | | | 2025 | 2024 | | | $ | $ | | Revenue | 937,354 | 24,380 | | Cost of revenue | (561,330) | (23,782) | | Gross profit | 376,024 | 598 | | Operating expenses | | | | Sales and marketing expenses | (1,4 ...

Financial Performance - Acadia Pharmaceuticals anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance[6] Corporate Events - The company presented at the J.P. Morgan Healthcare Conference on January 13, 2026[6] - A corporate slide presentation was posted on the company's investor website[6] Regulatory Filings - The report is filed under the Securities Exchange Act of 1934[8] - The company has not elected to use the extended transition period for new financial accounting standards[5] - No emerging growth company status was indicated in the filing[5] - The report includes a Regulation FD disclosure[7] - The financial statements and exhibits are part of the filing[9] - The report was signed by Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer & Secretary[13] Stock Information - Acadia Pharmaceuticals is listed on The Nasdaq Stock Market under the symbol ACAD[5]

Financial Performance - The company reported a revenue of $2.5 billion for Q2 2023, representing a 15% year-over-year increase[1]. - The company provided guidance for Q3 2023, expecting revenue to be between $2.6 billion and $2.8 billion, indicating a potential growth of 8% to 12%[3]. - Revenue from B2B sales for the three months ended November 30, 2025, was $183,923, a decrease of $9,923 compared to the same period in 2024, reflecting a shift away from B2B clients towards pharmaceuticals[136]. - The company reported a net loss of $1,597,503 for the three months ended November 30, 2025, compared to a net loss of $2,706,628 for the same period in 2024, indicating a reduction in losses year-over-year[131]. - The company incurred a net loss of $1,595,712 for the three months ended November 30, 2025, compared to a net loss of $2,706,628 for the same period in 2024[146]. - Net cash used in operating activities was approximately $1.0 million for the three months ended November 30, 2025, a significant decrease from $2.7 million in the same prior year period[143]. Research and Development - The company completed a Phase 1b clinical study showing good safety and tolerability of DehydraTECH formulated cannabidiol and semaglutide, with clear reductions in adverse events compared to the Rybelsus® control arm[117]. - Lexaria's DehydraTECH technology improves the delivery of Active Pharmaceutical Ingredients (APIs), potentially lowering overall dosing and enhancing bioavailability across various product categories[110]. - The company anticipates ongoing clinical research programs in cardiometabolic health, particularly for diabetes and weight loss treatments[113]. - The FDA provided a Study May Proceed letter for the IND application related to DehydraTECH-CBD for hypertension, allowing the company to advance its clinical trials[124]. - The company completed a human study (GLP-1-H24-4) with over 100 participants, demonstrating good safety and tolerability of DehydraTECH formulations compared to the Rybelsus® control arm[121]. - Long-term stability testing of DehydraTECH compositions is ongoing, with positive findings meeting internal expectations for chemical and microbiological purity[123]. - The company is exploring various therapeutic indications for DehydraTECH, including diabetes and weight loss treatments, with ongoing R&D programs[120]. - Research and development expenses increased by 12%, focusing on innovative technologies for product enhancement[7]. - Research and development expenditures decreased by $1,281,880 year-over-year for the three months ended November 30, 2025, as the company neared completion of its Phase 1b Clinical Trial[137]. Intellectual Property and Acquisitions - The company has several patents pending worldwide, specifically for the use of DehydraTECH with GLP-1/GIP drugs and cannabinoids for treating diabetes and heart disease[113]. - Lexaria's patent portfolio includes granted patents related to food and beverage compositions infused with lipophilic active agents, enhancing the effectiveness of API delivery[116]. - The company plans to continue seeking beneficial acquisitions of intellectual property to expand its portfolio[114]. - A strategic acquisition of a smaller competitor was completed, expected to contribute an additional $300 million in annual revenue[6]. Market Strategy and Expansion - The company is expanding its market presence in Asia, targeting a 20% increase in sales in the region by the end of 2024[5]. - New product launches included a line of enhanced delivery systems for lipophilic active agents, projected to increase market share by 5%[4]. - A new marketing strategy was implemented, aiming to boost brand awareness and customer engagement by 30% over the next year[9]. Financial Position and Funding - The company raised $3.4 million in net proceeds from a Registered Direct offering that closed in September 2025[132]. - The company has incurred recurring losses and negative cash flows from operations, with expectations of increased expenditures related to ongoing R&D programs, particularly for GLP-1 drugs and hypertension treatments[130]. - The company expects its current cash resources to fund operations through the first quarter of fiscal year 2027, but there is substantial doubt about its ability to continue as a going concern[133]. - The company plans to fund operations through equity financing arrangements and potential collaborations or strategic partnerships[149]. - Share issuance costs of $0.6 million were charged to additional paid-in capital during the recent financing[111]. - As of November 30, 2025, the company had current assets of $5,363,129 and current liabilities of $1,456,534, resulting in net working capital of $3,906,595[141]. - Cash and cash equivalents as of November 30, 2025, were approximately $4.3 million, which is expected to be insufficient to meet financial obligations for the next twelve months[149]. Operational Efficiency - The company reported a 25% increase in gross margin, attributed to improved operational efficiencies[8]. - Other general and administrative expenses decreased by $197,558, mainly due to lower spending on advertising and promotions[140]. - Consulting fees and salaries increased by $31,272 year-over-year, primarily due to cost of living adjustments, offset by reduced consulting fees and lower stock-based compensation[138]. - Legal and professional fees rose by $149,887 during the three months ended November 30, 2025, due to higher accounting and professional fees related to financing activities[139].

Drug Development - The company has four drug candidates in development targeting at least five different cancer indications and one obesity indication [67]. - The lead drug candidate, BP1001 (prexigebersen), is in a Phase 2 clinical trial for untreated acute myeloid leukemia (AML) patients, with a preliminary review showing 75% of newly diagnosed patients achieving complete remission or related outcomes [71]. - The Phase 2 trial includes three cohorts, with approximately 98 evaluable patients in the first cohort and 54 evaluable patients in each of the second and third cohorts [69]. - The second drug candidate, BP1002, targeting Bcl-2, has discontinued enrollment in its Phase 1 trial due to challenges in a crowded development landscape [72]. - BP1003, targeting the STAT3 protein, is in IND enabling studies for pancreatic cancer, with a focus on its potential as a treatment due to the severity of the disease [74]. - BP1001-A, a modified version of prexigebersen, is undergoing a Phase 1/1b trial, with the first cohort completed and no dose-limiting toxicities reported [75]. - The company is developing a molecular biomarker package to identify patients likely to respond to prexigebersen treatment, enhancing the probability of success [80]. - The company plans to expand its drug development programs to include new disease-causing protein targets and develop new liposomal antisense drug candidates [79]. Financial Performance - As of September 30, 2025, the company had an accumulated deficit of $126.0 million and a net loss of $1.0 million for the three months ended September 30, 2025, compared to a net loss of $2.1 million for the same period in 2024 [84]. - Research and development expenses for the three months ended September 30, 2025, were $0.3 million, a decrease of $1.0 million compared to the same period in 2024, primarily due to cash flow constraints and pausing clinical trials [97]. - General and administrative expenses for the three months ended September 30, 2025, were $0.2 million, a decrease of $1.1 million compared to the same period in 2024, mainly due to reduced salaries and benefits expenses [97]. - The company's net loss for the nine months ended September 30, 2025, was $8.4 million, a decrease of $1.3 million compared to the same period in 2024 [105]. - The company had a cash balance of $0.0 million as of September 30, 2025, a decrease of $1.2 million compared to December 31, 2024, indicating insufficient cash to meet obligations for the next 12 months [108]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $1.6 million, with a net loss for the period of $8.4 million [109]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $0.4 million, compared to $7.2 million for the same period in 2024 [112]. - The company expects to continue incurring significant operating losses as it expands drug development programs and commercialization efforts [84]. - The company currently has no lines of credit or arranged access to debt financing, relying on cash on hand and potential equity offerings for funding [107]. - The company anticipates that any revenue generated in the future will fluctuate based on the timing and success of drug candidate commercialization [89]. Financing Activities - The 2022 Shelf Registration Statement allows for the offering of up to $110.0 million in various securities, including common stock and warrants [113]. - On March 25, 2024, the company completed a registered direct offering of 75,000 shares for gross proceeds of approximately $0.3 million, with net proceeds of about $0.2 million after expenses [114]. - The At The Market Offering Agreement executed on April 4, 2024, resulted in the sale of 436,511 shares for gross proceeds of approximately $2.0 million, yielding net proceeds of around $1.8 million [115]. - As of June 30, 2025, the company sold 334,929 shares under the Subsequent ATM Prospectus Supplement for gross proceeds of approximately $1.1 million, with net proceeds of about $1.0 million [116]. - The April 2024 Registered Direct Offering raised approximately $1.2 million from the sale of 375,000 shares, with net proceeds of about $0.9 million after expenses [117]. - The June 2024 PIPE generated gross proceeds of approximately $4.0 million, with net proceeds of around $3.3 million after deducting fees and expenses [118]. - The October 2024 Private Placement raised approximately $4.0 million, resulting in net proceeds of about $3.5 million after expenses [119]. - In February 2025, investors exercised pre-funded warrants for 2,540,000 shares at a weighted average exercise price of approximately $0.001 per share [120]. - The company anticipates significant operating expenses related to clinical trials and regulatory approvals, necessitating substantial additional capital [127]. Compliance and Risk - As of September 30, 2025, the March 2025 Promissory Notes were in default and became convertible under the default provisions [126]. - As of September 30, 2025, the company reported no material off-balance sheet arrangements [128]. - There have been no significant changes to the company's critical accounting policies since the last annual report [129]. - The company did not disclose any quantitative or qualitative market risk information [130].

Financial Performance - RCI Hospitality Holdings, Inc. reported sales at nightclubs and restaurants for the first fiscal quarter ended December 31, 2025[4]. - The report does not include specific financial figures or performance metrics in the provided content[4]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3]. Stock Information - The common stock of RCI Hospitality Holdings is traded under the symbol RICK on the Nasdaq Global Market[2]. Press Release - The press release detailing financial results was issued on January 13, 2026[4].

Financial Performance - Total net sales for the nine months ended November 30, 2025, were $15,299,839, a slight decrease of 0.5% compared to $15,383,416 for the same period in 2024[13] - Gross profit for the nine months ended November 30, 2025, increased to $7,766,492, representing a gross margin of 50.8%, compared to $7,313,783 and a margin of 47.6% in 2024[13] - Operating income for the nine months ended November 30, 2025, was $1,223,494, up 69.5% from $721,923 in the same period last year[13] - Net income for the nine months ended November 30, 2025, was $1,248,637, an increase of 32.1% compared to $945,700 in 2024[13] - Basic earnings per share for the nine months ended November 30, 2025, were $0.08, compared to $0.06 for the same period in 2024[13] Cash and Liquidity - Cash and cash equivalents as of November 30, 2025, were $5,395,695, up from $5,202,361 as of February 28, 2025[11] - Total current assets increased to $20,093,512 as of November 30, 2025, compared to $18,988,465 as of February 28, 2025, reflecting a growth of 5.8%[11] - Cash and cash equivalents at the end of the period were $5,395,695, down from $8,098,750 at the end of the previous year, reflecting a decrease of approximately 33%[20] - The company generated net cash provided by operating activities of $109,661 for the nine months ended November 30, 2025, a significant decrease from $1,199,318 in the prior year[20] Assets and Liabilities - Total liabilities decreased to $4,798,194 as of November 30, 2025, from $5,619,441 as of February 28, 2025, a reduction of 14.6%[11] - Total stockholders' equity rose to $19,132,420 as of November 30, 2025, compared to $17,792,195 as of February 28, 2025, indicating an increase of 7.5%[11] - The company’s total assets increased from $16,278,998 on February 29, 2024, to $19,132,420 on November 30, 2025, indicating a growth of approximately 17%[18] Research and Development - Research and product development costs for the nine months ended November 30, 2025, were $1,934,109, a decrease of 5.8% from $2,054,846 in 2024[13] - Research and product development expenses for the nine months ended November 30, 2025, were $1,934,000, compared to $2,055,000 in 2024[67] Inventory and Receivables - The company’s inventory reserve increased to $45,927 from $32,524 year-over-year, representing a rise of approximately 41%[20] - The company’s accounts receivable increased significantly by $2,063,899 compared to $808,594 in the prior year, indicating a rise of approximately 155%[20] - The Company’s inventories totaled $3,656,898 as of November 30, 2025, down from $4,474,401 as of February 28, 2025, representing a decrease of approximately 18.3%[51] Sales and Revenue - Total sales revenue for the three months ended November 30, 2025, was $5,004,000, a decrease from $5,191,000 in the same period of 2024[50] - For the nine months ended November 30, 2025, total sales revenue was $15,300,000, compared to $15,383,000 for the same period in 2024[50] - Export sales to foreign customers for the nine months ended November 30, 2025, totaled $5,626,000, accounting for 37% of total revenues[63] Customer Concentration - One customer accounted for 38% of sales during the first nine months of fiscal 2026, indicating significant customer concentration risk[64] Stock and Compensation - The weighted average grant date fair value of stock options granted during the nine months ended November 30, 2025, was $3.26 per share[56] - The company reported stock-based compensation expenses of $232,097 for the nine months ended November 30, 2025, compared to $176,076 for the same period in 2024, marking a 32% increase[20] Tax and Regulatory - The company plans to leverage the changes introduced by the One Big Beautiful Bill Act to enhance its tax position and reduce current tax payable for capital expenditures in fiscal year 2026[33]

Financial Performance - Castle Biosciences, Inc. announced preliminary performance results for Q4 2025 and the year ended December 31, 2025[5] - The report does not include specific financial figures or performance metrics in the provided content[5] Company Information - The company is listed on the Nasdaq Global Market under the symbol CSTL[3] - The press release detailing the financial results was issued on January 11, 2026[5] - The company has made available a slide presentation for future meetings regarding its performance[7]

Sales Performance - Royal Gold's consolidated stream segment sales for Q4 2025 were approximately 64,000 gold equivalent ounces (GEOs), with 58,200 GEOs from RGLD Gold AG and 5,800 GEOs from the Sandstorm portfolio[2][3]. - Total stream segment sales for the year 2025 reached approximately 195,400 GEOs[3]. Pricing Information - The average realized price for gold in Q4 2025 was $4,071 per ounce for RGLD Gold AG and $4,240 per ounce for the Sandstorm portfolio, while silver averaged $50.90 per ounce and $66.79 per ounce respectively[2]. Financial Position - Royal Gold reduced outstanding borrowings by $400 million since the Sandstorm transaction, with an outstanding balance of $900 million as of December 31, 2025, and further reduced to $825 million after an additional repayment[4][5]. Asset Management - The company is rationalizing non-core assets acquired from the Sandstorm transaction, including restructuring agreements with Bear Creek Mining Corporation to increase royalty exposure[7][8]. - Royal Gold will receive $6.2 million in cash and an incremental 1.75% net smelter return royalty on the Corani Project in Peru as part of the Bear Creek restructuring[8]. Future Outlook - The anticipated closing of the Highlander/Bear Creek transaction is expected to create a larger, well-capitalized company better positioned for future growth[9]. - Royal Gold's Q4 2025 financial results will be released on February 18, 2026, followed by a conference call on February 19, 2026[10].